Doxy-PEP: Who, When, and How? (On-Demand)

Assessment of Needs

Given the increasing burden of gonorrhea, chlamydia, and syphilis infections in the US, effective tools are needed to fight against bacterial sexually transmitted infections (STIs). Doxycycline postexposure prophylaxis (doxy-PEP) is a sexual-health strategy that shows considerable promise in this endeavor. Drug formulations and recommendations for use continue to evolve, particularly for patients with HIV. Presented by Annie Luetkemeyer, MD, and moderated by Connie Celum, MD, this webinar reviewed the current recommendations by the Centers for Disease Control and Prevention (CDC) for the use of doxy-PEP. Topics includee the criteria to determine appropriate candidates for doxy-PEP therapy, strategies for effective doxy-PEP administration, and questions that remain to be answered in future studies on doxy-PEP in patients with HIV.

Learning Objectives

 On completion of this activity, learners will be able to: 

• Describe how and when to utilize doxycycline postexposure prophylaxis (doxy-PEP) to reduce the incidence of certain bacterial sexually transmitted infections
• Implement a practical approach to doxy-PEP prescribing in appropriate patients
• List current unanswered questions regarding doxy-PEP use in patients with HIV

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Luetkemeyer reported grants/grants pending to their institution from Gilead Sciences, Inc, and GlaxoSmithKline; consulting or advisor fees from Vir Biotechnology; non-cash provision of medicines, equipment, or administrative support to their institution from Mayne Pharma, Hologic, and Cepheid. (Updated July 26, 2023)

Moderator

Dr Celum reported consulting or advising fees from Gilead Sciences, Inc. and Merck & Co, Inc; and expert testimony for Gilead Sciences, Inc. (Updated June 30, 2023)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/